ReviewCurrent neurology and neuroscience reports2019
Gray Matter Changes in Parkinson's and Alzheimer's Disease and Relation to Cognition.
Review in Current neurology and neuroscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- The global research of magnetic resonance imaging in Alzheimer's disease: a bibliometric analysis from 2004 to 2023.Frontiers in neurology · 2024Pooled it
- Cognition effectiveness of continuous positive airway pressure treatment in obstructive sleep apnea syndrome patients with cognitive impairment: a meta-analysis.Experimental brain research · 2021Pooled it
- Periventricular gradient of normal-appearing white matter in normal aging and multiple neurological diseases.Journal of advanced research · 2026Article
- Investigation of the myelin-amyloid interplay in Alzheimer's disease: insights from novel dsCMA imaging in mouse and human brains.Acta neuropathologica communications · 2026Article
- The causal relationship between neuroimaging and Parkinson's disease: A two-sample Mendelian randomization study.Medicine · 2026Article
- Differential cued recall memory impairment in mild cognitive impairment due to Alzheimer's disease versus Parkinson's disease.Journal of neuropsychology · 2026Article
- Charting brain morphology in international healthy and neurological populations.Nature neuroscience · 2026Article
- Article
- Neuroimaging and Pathology Biomarkers in Parkinson's Disease and Parkinsonism.Brain sciences · 2026Article
- PredatorNet: a clinically trustworthy deep learning framework for multi-class Alzheimer's disease classification using MRI.Frontiers in aging neuroscience · 2026Article
- Genetic polymorphism in β-site amyloid precursor protein-cleaving enzyme 1 affects the structure of medial temporal lobe and cognition in Alzheimer's disease: an exploratory study.European archives of psychiatry and clinical neuroscience · 2025Article
- Non-invasive brain stimulation: current and future applications in neurology.Nature reviews. Neurology · 2025Review
- Late-Stage Activation of Toll-like receptor 3 Alleviates Cognitive Impairment and Neuropathology in an Alzheimer's Disease Mouse Model.Molecular neurobiology · 2025Article
- Longitudinal Changes of Quantitative Brain Tissue Properties Induced by Balance Training.Human brain mapping · 2025Article
- Exome sequencing identifies novel genes associated with cerebellar volume and microstructure.Communications biology · 2025Article
- Article
- Structural and microstructural changes in white and gray matter across the Alzheimer's disease continuum.Frontiers in aging neuroscience · 2025Review
- Link among apolipoprotein E E4, gait, and cognition in neurodegenerative diseases: ONDRI study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The longitudinal volumetric and shape changes of subcortical nuclei in Parkinson's disease.Scientific reports · 2024Article
- Morphometric similarity differences in drug-naive Parkinson's disease correlate with transcriptomic signatures.CNS neuroscience & therapeutics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewWe summarize structural (s)MRI findings of gray matter (GM) atrophy related to cognitive impairment in Alzheimer's disease (AD) and Parkinson's disease (PD) in light of new analytical approaches and recent longitudinal studies results. RECENT
findingsThe hippocampus-to-cortex ratio seems to be the best sMRI biomarker to discriminate between various AD subtypes, following the spatial distribution of tau pathology, and predict rate of cognitive decline. PD is clinically far more variable than AD, with heterogeneous underlying brain pathology. Novel multivariate approaches have been used to describe patterns of early subcortical and cortical changes that relate to more malignant courses of PD. New emerging analytical approaches that combine structural MRI data with clinical and other biomarker outcomes hold promise for detecting specific GM changes in the early stages of PD and preclinical AD that may predict mild cognitive impairment and dementia conversion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.